Fidelity Investments
CLYM

Fidelity Investments’s Climb Bio CLYM Stock Holding History

Fidelity Investments’s Portfolio CLYM Stock Details CLYM Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$43.8K Buy
6,397
+48
+0.8% +$277 ﹤0.01% 4183
2025
Q4 		$25.4K Sell
6,349
-793
-11% -$1.9K ﹤0.01% 4376
2025
Q3 		$14.4K Sell
7,142
-485
-6% -$900 ﹤0.01% 4493
2025
Q2 		$9.46K Buy
7,627
+4,977
+188% +$6.19K ﹤0.01% 4544
2025
Q1 		$3.23K Sell
2,650
-10,913
-80% -$17.7K ﹤0.01% 4804
2024
Q4 		$24.4K Buy
13,563
+13,547
+84,669% +$49K ﹤0.01% 4135
2024
Q3 		$81 Buy
+16
New +$113 ﹤0.01% 5121
2022
Q3 		– Sell
-9
Closed – – 5490
2022
Q2 		$0 Sell
9
-85
-90% -$402 ﹤0.01% 5580
2022
Q1 		$1K Buy
+94
New +$877 ﹤0.01% 4864

Other funds holding CLYM

RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
MB
MPM BioImpact Boston, Massachusetts $1.29B AUM 141.72% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
B
Braidwell Stamford, Connecticut $3B AUM 46.72% 1-Year Est. Return
GPP
Great Point Partners Greenwich, Connecticut $408M AUM 318.81% 1-Year Est. Return
Millennium Management
Millennium Management New York $134B AUM 35.51% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
KCM
Kynam Capital Management Princeton, New Jersey $1.58B AUM 138.67% 1-Year Est. Return
Marshall Wace
Marshall Wace London, United Kingdom $93.4B AUM 35.1% 1-Year Est. Return
AAA
Affinity Asset Advisors New York $1.71B AUM 374.45% 1-Year Est. Return